CompletedPhase 2NCT02072668

The Effect of Rivaroxaban in Sickle Cell Disease

Studying Sickle cell anemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of North Carolina, Chapel Hill
Principal Investigator
Kenneth I Ataga, MBBS
University of North Carolina, Chapel Hill
Intervention
rivaroxaban(drug)
Enrollment
14 enrolled
Eligibility
18-65 years · All sexes
Timeline
2014 – 2018

Study locations (1)

Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02072668 on ClinicalTrials.gov

Other trials for Sickle cell anemia

Additional recruiting or active studies for the same condition.

See all trials for Sickle cell anemia →

← Back to all trials